Proactive analyst Emma Ulker talks to Proactive London about Open Orphan (LON:ORPH).
She says ORPH has firmly established its core pharma services offering, underpinned
by the world-leading quarantine facilities, unique challenge study models and its established clinical trial services.
ORPH is focusing on converting an extensive and substantial amount of non-Covid-19 related services worth over £100mln. This is in addition to substantial contracts already
signed with the UK Government for COVID-19 vaccine challenge studies.